Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.

Byun NE, Grannan M, Bubser M, Barry RL, Thompson A, Rosanelli J, Gowrishankar R, Kelm ND, Damon S, Bridges TM, Melancon BJ, Tarr JC, Brogan JT, Avison MJ, Deutch AY, Wess J, Wood MR, Lindsley CW, Gore JC, Conn PJ, Jones CK.

Neuropsychopharmacology. 2014 Jun;39(7):1578-93. doi: 10.1038/npp.2014.2. Epub 2014 Jan 20.

2.

Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.

Bubser M, Bridges TM, Dencker D, Gould RW, Grannan M, Noetzel MJ, Lamsal A, Niswender CM, Daniels JS, Poslusney MS, Melancon BJ, Tarr JC, Byers FW, Wess J, Duggan ME, Dunlop J, Wood MW, Brandon NJ, Wood MR, Lindsley CW, Conn PJ, Jones CK.

ACS Chem Neurosci. 2014 Oct 15;5(10):920-42. doi: 10.1021/cn500128b. Epub 2014 Aug 19.

3.

An allosteric enhancer of M₄ muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine.

Dencker D, Weikop P, Sørensen G, Woldbye DP, Wörtwein G, Wess J, Fink-Jensen A.

Psychopharmacology (Berl). 2012 Nov;224(2):277-87. doi: 10.1007/s00213-012-2751-8. Epub 2012 May 31.

4.

Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats.

Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey JK, Conn PJ, Lindsley CW.

J Pharmacol Exp Ther. 2008 Dec;327(3):941-53. doi: 10.1124/jpet.108.140350. Epub 2008 Sep 4.

5.

Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.

Dencker D, Wörtwein G, Weikop P, Jeon J, Thomsen M, Sager TN, Mørk A, Woldbye DP, Wess J, Fink-Jensen A.

J Neurosci. 2011 Apr 20;31(16):5905-8. doi: 10.1523/JNEUROSCI.0370-11.2011.

6.

Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.

Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA.

Eur J Pharmacol. 2009 Jan 28;603(1-3):147-9. doi: 10.1016/j.ejphar.2008.12.020. Epub 2008 Dec 16.

PMID:
19111716
7.

The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype.

Watt ML, Rorick-Kehn L, Shaw DB, Knitowski KM, Quets AT, Chesterfield AK, McKinzie DL, Felder CC.

Neuropsychopharmacology. 2013 Dec;38(13):2717-26. doi: 10.1038/npp.2013.186. Epub 2013 Aug 2.

8.

Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.

Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, Sexton PM, Christopoulos A.

Neuropsychopharmacology. 2010 Mar;35(4):855-69. doi: 10.1038/npp.2009.194. Epub 2009 Nov 25.

9.

The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.

Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM, Wyatt A.

J Pharmacol Exp Ther. 2001 Nov;299(2):782-92.

10.

N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.

Gregory KJ, Herman EJ, Ramsey AJ, Hammond AS, Byun NE, Stauffer SR, Manka JT, Jadhav S, Bridges TM, Weaver CD, Niswender CM, Steckler T, Drinkenburg WH, Ahnaou A, Lavreysen H, Macdonald GJ, Bartolomé JM, Mackie C, Hrupka BJ, Caron MG, Daigle TL, Lindsley CW, Conn PJ, Jones CK.

J Pharmacol Exp Ther. 2013 Nov;347(2):438-57. doi: 10.1124/jpet.113.206623. Epub 2013 Aug 21.

11.

Effects of selective activation of M1 and M4 muscarinic receptors on object recognition memory performance in rats.

Galloway CR, Lebois EP, Shagarabi SL, Hernandez NA, Manns JR.

Pharmacology. 2014;93(1-2):57-64. doi: 10.1159/000357682. Epub 2014 Jan 25.

PMID:
24480931
12.
13.

Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor.

Huynh T, Valant C, Crosby IT, Sexton PM, Christopoulos A, Capuano B.

J Med Chem. 2013 Oct 24;56(20):8196-200. doi: 10.1021/jm401032k. Epub 2013 Oct 11.

PMID:
24074052
14.
15.

Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.

Suratman S, Leach K, Sexton P, Felder C, Loiacono R, Christopoulos A.

Br J Pharmacol. 2011 Apr;162(7):1659-70. doi: 10.1111/j.1476-5381.2010.01184.x.

16.

An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission.

Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM, Conn PJ.

Nat Chem Biol. 2008 Jan;4(1):42-50. Epub 2007 Dec 2.

PMID:
18059262
17.

New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug).

Nawaratne V, Leach K, Suratman N, Loiacono RE, Felder CC, Armbruster BN, Roth BL, Sexton PM, Christopoulos A.

Mol Pharmacol. 2008 Oct;74(4):1119-31. doi: 10.1124/mol.108.049353. Epub 2008 Jul 15.

18.

Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.

Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ.

J Neurosci. 2008 Oct 8;28(41):10422-33. doi: 10.1523/JNEUROSCI.1850-08.2008.

19.

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83. doi: 10.1073/pnas.0800567105. Epub 2008 Aug 4.

20.

A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.

Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr.

J Pharmacol Exp Ther. 2005 Apr;313(1):199-206. Epub 2004 Dec 17.

Items per page

Supplemental Content

Write to the Help Desk